1
|
Nassauer L, Staecker H, Huang P, Renslo B, Goblet M, Harre J, Warnecke A, Schott JW, Morgan M, Galla M, Schambach A. Protection from cisplatin-induced hearing loss with lentiviral vector-mediated ectopic expression of the anti-apoptotic protein BCL-XL. Mol Ther Nucleic Acids 2024; 35:102157. [PMID: 38450280 PMCID: PMC10915631 DOI: 10.1016/j.omtn.2024.102157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Accepted: 02/15/2024] [Indexed: 03/08/2024]
Abstract
Cisplatin is a highly effective chemotherapeutic agent, but it can cause sensorineural hearing loss (SNHL) in patients. Cisplatin-induced ototoxicity is closely related to the accumulation of reactive oxygen species (ROS) and subsequent death of hair cells (HCs) and spiral ganglion neurons (SGNs). Despite various strategies to combat ototoxicity, only one therapeutic agent has thus far been clinically approved. Therefore, we have developed a gene therapy concept to protect cochlear cells from cisplatin-induced toxicity. Self-inactivating lentiviral (LV) vectors were used to ectopically express various antioxidant enzymes or anti-apoptotic proteins to enhance the cellular ROS scavenging or prevent apoptosis in affected cell types. In direct comparison, anti-apoptotic proteins mediated a stronger reduction in cytotoxicity than antioxidant enzymes. Importantly, overexpression of the most promising candidate, Bcl-xl, achieved an up to 2.5-fold reduction in cisplatin-induced cytotoxicity in HEI-OC1 cells, phoenix auditory neurons, and primary SGN cultures. BCL-XL protected against cisplatin-mediated tissue destruction in cochlear explants. Strikingly, in vivo application of the LV BCL-XL vector improved hearing and increased HC survival in cisplatin-treated mice. In conclusion, we have established a preclinical gene therapy approach to protect mice from cisplatin-induced ototoxicity that has the potential to be translated to clinical use in cancer patients.
Collapse
Affiliation(s)
- Larissa Nassauer
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Hinrich Staecker
- Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, KS 66160, USA
| | - Peixin Huang
- Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, KS 66160, USA
| | - Bryan Renslo
- Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, KS 66160, USA
| | - Madeleine Goblet
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
- Cluster of Excellence “Hearing4all”, Hannover Medical School, 30625 Hannover, Germany
| | - Jennifer Harre
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
- Cluster of Excellence “Hearing4all”, Hannover Medical School, 30625 Hannover, Germany
| | - Athanasia Warnecke
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
- Cluster of Excellence “Hearing4all”, Hannover Medical School, 30625 Hannover, Germany
| | - Juliane W. Schott
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Michael Morgan
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Melanie Galla
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Axel Schambach
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
- Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
2
|
Tropitzsch A, Schade-Mann T, Gamerdinger P, Dofek S, Schulte B, Schulze M, Fehr S, Biskup S, Haack TB, Stöbe P, Heyd A, Harre J, Lesinski-Schiedat A, Büchner A, Lenarz T, Warnecke A, Müller M, Vona B, Dahlhoff E, Löwenheim H, Holderried M. Variability in Cochlear Implantation Outcomes in a Large German Cohort With a Genetic Etiology of Hearing Loss. Ear Hear 2023; 44:1464-1484. [PMID: 37438890 PMCID: PMC10583923 DOI: 10.1097/aud.0000000000001386] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 04/04/2023] [Indexed: 07/14/2023]
Abstract
OBJECTIVES The variability in outcomes of cochlear implantation is largely unexplained, and clinical factors are not sufficient for predicting performance. Genetic factors have been suggested to impact outcomes, but the clinical and genetic heterogeneity of hereditary hearing loss makes it difficult to determine and interpret postoperative performance. It is hypothesized that genetic mutations that affect the neuronal components of the cochlea and auditory pathway, targeted by the cochlear implant (CI), may lead to poor performance. A large cohort of CI recipients was studied to verify this hypothesis. DESIGN This study included a large German cohort of CI recipients (n = 123 implanted ears; n = 76 probands) with a definitive genetic etiology of hearing loss according to the American College of Medical Genetics (ACMG)/Association for Molecular Pathology (AMP) guidelines and documented postoperative audiological outcomes. All patients underwent preoperative clinical and audiological examinations. Postoperative CI outcome measures were based on at least 1 year of postoperative audiological follow-up for patients with postlingual hearing loss onset (>6 years) and 5 years for children with congenital or pre/perilingual hearing loss onset (≤6 years). Genetic analysis was performed based on three different methods that included single-gene screening, custom-designed hearing loss gene panel sequencing, targeting known syndromic and nonsyndromic hearing loss genes, and whole-genome sequencing. RESULTS The genetic diagnosis of the 76 probands in the genetic cohort involved 35 genes and 61 different clinically relevant (pathogenic, likely pathogenic) variants. With regard to implanted ears (n = 123), the six most frequently affected genes affecting nearly one-half of implanted ears were GJB2 (21%; n = 26), TMPRSS3 (7%; n = 9), MYO15A (7%; n = 8), SLC26A4 (5%; n = 6), and LOXHD1 and USH2A (each 4%; n = 5). CI recipients with pathogenic variants that influence the sensory nonneural structures performed at or above the median level of speech performance of all ears at 70% [monosyllable word recognition score in quiet at 65 decibels sound pressure level (SPL)]. When gene expression categories were compared to demographic and clinical categories (total number of compared categories: n = 30), mutations in genes expressed in the spiral ganglion emerged as a significant factor more negatively affecting cochlear implantation outcomes than all clinical parameters. An ANOVA of a reduced set of genetic and clinical categories (n = 10) identified five detrimental factors leading to poorer performance with highly significant effects ( p < 0.001), accounting for a total of 11.8% of the observed variance. The single strongest category was neural gene expression accounting for 3.1% of the variance. CONCLUSIONS The analysis of the relationship between the molecular genetic diagnoses of a hereditary etiology of hearing loss and cochlear implantation outcomes in a large German cohort of CI recipients revealed significant variabilities. Poor performance was observed with genetic mutations that affected the neural components of the cochlea, supporting the "spiral ganglion hypothesis."
Collapse
Affiliation(s)
- Anke Tropitzsch
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Hearing Center, Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Center for Rare Hearing Disorders, Centre for Rare Diseases, University of Tübingen, Tübingen, Germany
- Neurosensory Center, Departments of Otolaryngology—Head & Neck Surgery and Ophthalmology, University of Tübingen Medical Center, Tübingen, Germany
| | - Thore Schade-Mann
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Hearing Center, Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
| | - Philipp Gamerdinger
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Hearing Center, Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
| | - Saskia Dofek
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
| | - Björn Schulte
- CeGaT GmbH und Praxis für Humangenetik Tübingen, Tübingen, Germany
| | - Martin Schulze
- CeGaT GmbH und Praxis für Humangenetik Tübingen, Tübingen, Germany
| | - Sarah Fehr
- CeGaT GmbH und Praxis für Humangenetik Tübingen, Tübingen, Germany
| | - Saskia Biskup
- CeGaT GmbH und Praxis für Humangenetik Tübingen, Tübingen, Germany
| | - Tobias B. Haack
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Petra Stöbe
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Andreas Heyd
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
| | - Jennifer Harre
- Department of Otorhinolaryngology—Head & Neck Surgery, Hannover Medical School, Hannover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation, Hannover, Germany
| | - Anke Lesinski-Schiedat
- Department of Otorhinolaryngology—Head & Neck Surgery, Hannover Medical School, Hannover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation, Hannover, Germany
| | - Andreas Büchner
- Department of Otorhinolaryngology—Head & Neck Surgery, Hannover Medical School, Hannover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation, Hannover, Germany
| | - Thomas Lenarz
- Department of Otorhinolaryngology—Head & Neck Surgery, Hannover Medical School, Hannover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation, Hannover, Germany
| | - Athanasia Warnecke
- Department of Otorhinolaryngology—Head & Neck Surgery, Hannover Medical School, Hannover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation, Hannover, Germany
| | - Marcus Müller
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Neurosensory Center, Departments of Otolaryngology—Head & Neck Surgery and Ophthalmology, University of Tübingen Medical Center, Tübingen, Germany
| | - Barbara Vona
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Neurosensory Center, Departments of Otolaryngology—Head & Neck Surgery and Ophthalmology, University of Tübingen Medical Center, Tübingen, Germany
| | - Ernst Dahlhoff
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Neurosensory Center, Departments of Otolaryngology—Head & Neck Surgery and Ophthalmology, University of Tübingen Medical Center, Tübingen, Germany
| | - Hubert Löwenheim
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Neurosensory Center, Departments of Otolaryngology—Head & Neck Surgery and Ophthalmology, University of Tübingen Medical Center, Tübingen, Germany
| | - Martin Holderried
- Department of Otolaryngology—Head & Neck Surgery, University of Tübingen Medical Center, Tübingen, Germany
- Department of Medical Development and Quality Management, University Hospital Tübingen, Tübingen, Germany
| |
Collapse
|
3
|
Wang D, Wang H, Fan L, Ludwig T, Wegner A, Stahl F, Harre J, Warnecke A, Zeilinger C. A Chemical Chaperone Restores Connexin 26 Mutant Activity. ACS Pharmacol Transl Sci 2023; 6:997-1005. [PMID: 37470015 PMCID: PMC10353060 DOI: 10.1021/acsptsci.3c00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Indexed: 07/21/2023]
Abstract
Mutations in connexin 26 (Cx26) cause hearing disorders of a varying degree. Herein, to identify compounds capable of restoring the function of mutated Cx26, a novel miniaturized microarray-based screening system was developed to perform an optical assay of Cx26 functionality. These molecules were identified through a viability assay using HeLa cells expressing wild-type (WT) Cx26, which exhibited sensitivity toward the HSP90 inhibitor radicicol in the submicromolar concentration range. Open Cx26 hemichannels are assumed to mediate the passage of molecules up to 1000 Da in size. Thus, by releasing radicicol, WT Cx26 active hemichannels in HeLa cells contribute to a higher survival rate and lower cell viability when Cx26 is mutated. HeLa cells expressing Cx26 mutations exhibited reduced viability in the presence of radicicol, such as the mutants F161S or R184P. Next, molecules exhibiting chemical chaperoning activity, suspected of restoring channel function, were assessed regarding whether they induced superior sensitivity toward radicicol and increased HeLa cell viability. Through a viability assay and microarray-based flux assay that uses Lucifer yellow in HeLa cells, compounds 3 and 8 were identified to restore mutant functionality. Furthermore, thermophoresis experiments revealed that only 3 (VRT-534) exhibited dose-responsive binding to recombinant WT Cx26 and mutant Cx26K188N with half maximal effective concentration values of 19 and ∼5 μM, respectively. The findings of this study reveal that repurposing compounds already being used to treat other diseases, such as cystic fibrosis, in combination with functional bioassays and binding tests can help identify novel potential candidates that can be used to treat hearing disorders.
Collapse
Affiliation(s)
- Dahua Wang
- Gottfried-Wilhelm-Leibniz
University of Hannover, BMWZ (Zentrum für
Biomolekulare Wirkstoffe), Schneiderberg 38, 30167 Hannover, Germany
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), 30625 Hannover, Germany
| | - Hongling Wang
- Gottfried-Wilhelm-Leibniz
University of Hannover, BMWZ (Zentrum für
Biomolekulare Wirkstoffe), Schneiderberg 38, 30167 Hannover, Germany
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), 30625 Hannover, Germany
| | - Lu Fan
- Gottfried-Wilhelm-Leibniz
University of Hannover, BMWZ (Zentrum für
Biomolekulare Wirkstoffe), Schneiderberg 38, 30167 Hannover, Germany
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), 30625 Hannover, Germany
| | - Tobias Ludwig
- Technische
Universität Braunschweig, Braunschweig Integrated Centre of
Systems Biology (BRICS), Department of Bioinformatics
and Biochemistry, Rebenring
56, 38106 Braunschweig, Germany
| | - Andre Wegner
- Technische
Universität Braunschweig, Braunschweig Integrated Centre of
Systems Biology (BRICS), Department of Bioinformatics
and Biochemistry, Rebenring
56, 38106 Braunschweig, Germany
| | - Frank Stahl
- Gottfried-Wilhelm-Leibniz
University of Hannover, Institut für
Technische Chemie/BMWZ (Zentrum für Biomolekulare Wirkstoffe), Callinstr. 5, 30167 Hannover, Germany
| | - Jennifer Harre
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), 30625 Hannover, Germany
| | - Athanasia Warnecke
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), 30625 Hannover, Germany
| | - Carsten Zeilinger
- Gottfried-Wilhelm-Leibniz
University of Hannover, BMWZ (Zentrum für
Biomolekulare Wirkstoffe), Schneiderberg 38, 30167 Hannover, Germany
| |
Collapse
|
4
|
Harre J, Heinkele L, Steffens M, Warnecke A, Lenarz T, Just I, Rohrbeck A. Corrigendum: Potentiation of brain-derived neurotrophic factor-induced protection of spiral ganglion neurons by C3 exoenzyme/Rho inhibitor. Front Cell Neurosci 2022; 16:1078962. [DOI: 10.3389/fncel.2022.1078962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 10/25/2022] [Indexed: 11/06/2022] Open
|
5
|
Fan L, Kishore A, Jansen-Olliges L, Wang D, Stahl F, Psathaki OE, Harre J, Warnecke A, Weder J, Preller M, Zeilinger C. Identification of a Thyroid Hormone Binding Site in Hsp90 with Implications for Its Interaction with Thyroid Hormone Receptor Beta. ACS Omega 2022; 7:28932-28945. [PMID: 36033668 PMCID: PMC9404468 DOI: 10.1021/acsomega.2c02331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 07/19/2022] [Indexed: 06/15/2023]
Abstract
While many proteins are known clients of heat shock protein 90 (Hsp90), it is unclear whether the transcription factor, thyroid hormone receptor beta (TRb), interacts with Hsp90 to control hormonal perception and signaling. Higher Hsp90 expression in mouse fibroblasts was elicited by the addition of triiodothyronine (T3). T3 bound to Hsp90 and enhanced adenosine triphosphate (ATP) binding of Hsp90 due to a specific binding site for T3, as identified by molecular docking experiments. The binding of TRb to Hsp90 was prevented by T3 or by the thyroid mimetic sobetirome. Purified recombinant TRb trapped Hsp90 from cell lysate or purified Hsp90 in pull-down experiments. The affinity of Hsp90 for TRb was 124 nM. Furthermore, T3 induced the release of bound TRb from Hsp90, which was shown by streptavidin-conjugated quantum dot (SAv-QD) masking assay. The data indicate that the T3 interaction with TRb and Hsp90 may be an amplifier of the cellular stress response by blocking Hsp90 activity.
Collapse
Affiliation(s)
- Lu Fan
- BMWZ
(Zentrum für Biomolekulare Wirkstoffe), Gottfried-Wilhelm-Leibniz University of Hannover, Hannover 30167, Germany
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), Hannover 30625, Germany
| | - Anusha Kishore
- BMWZ
(Zentrum für Biomolekulare Wirkstoffe), Gottfried-Wilhelm-Leibniz University of Hannover, Hannover 30167, Germany
| | - Linda Jansen-Olliges
- BMWZ
(Zentrum für Biomolekulare Wirkstoffe), Gottfried-Wilhelm-Leibniz University of Hannover, Hannover 30167, Germany
| | - Dahua Wang
- BMWZ
(Zentrum für Biomolekulare Wirkstoffe), Gottfried-Wilhelm-Leibniz University of Hannover, Hannover 30167, Germany
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), Hannover 30625, Germany
| | - Frank Stahl
- Institut
für Technische Chemie, Gottfried-Wilhelm-Leibniz
University of Hannover, Hannover 30167, Germany
| | - Olympia Ekaterini Psathaki
- Center
of Cellular Nanoanalytics, Integrated Bioimaging Facility, University of Osnabrück, Osnabrück 49076, Germany
| | - Jennifer Harre
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), Hannover 30625, Germany
| | - Athanasia Warnecke
- Clinic
for Otorhinolaryngology Surgery, Hannover
Medical School (MHH), Hannover 30625, Germany
| | - Julia Weder
- Institute
for Biophysical Chemistry, Hannover Medical
School, Carl-Neuberg-Straβe
1, Hannover 30625, Germany
- Institute
for Functional Gene Analytics (IFGA), Department of Natural Sciences, University of Applied Sciences Bonn-Rhein-Sieg, Von-Liebig-Str. 20, Rheinbach 53359, Germany
| | - Matthias Preller
- Institute
for Biophysical Chemistry, Hannover Medical
School, Carl-Neuberg-Straβe
1, Hannover 30625, Germany
- Institute
for Functional Gene Analytics (IFGA), Department of Natural Sciences, University of Applied Sciences Bonn-Rhein-Sieg, Von-Liebig-Str. 20, Rheinbach 53359, Germany
| | - Carsten Zeilinger
- BMWZ
(Zentrum für Biomolekulare Wirkstoffe), Gottfried-Wilhelm-Leibniz University of Hannover, Hannover 30167, Germany
| |
Collapse
|
6
|
St. Peter M, Brough DE, Lawrence A, Nelson-Brantley J, Huang P, Harre J, Warnecke A, Staecker H. Improving Control of Gene Therapy-Based Neurotrophin Delivery for Inner Ear Applications. Front Bioeng Biotechnol 2022; 10:892969. [PMID: 35721868 PMCID: PMC9204055 DOI: 10.3389/fbioe.2022.892969] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 04/27/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Survival and integrity of the spiral ganglion is vital for hearing in background noise and for optimal functioning of cochlear implants. Numerous studies have demonstrated that supplementation of supraphysiologic levels of the neurotrophins BDNF and NT-3 by pumps or gene therapy strategies supports spiral ganglion survival. The endogenous physiological levels of growth factors within the inner ear, although difficult to determine, are likely extremely low within the normal inner ear. Thus, novel approaches for the long-term low-level delivery of neurotrophins may be advantageous. Objectives: This study aimed to evaluate the long-term effects of gene therapy-based low-level neurotrophin supplementation on spiral ganglion survival. Using an adenovirus serotype 28-derived adenovector delivery system, the herpes latency promoter, a weak, long expressing promoter system, has been used to deliver the BDNF or NTF3 genes to the inner ear after neomycin-induced ototoxic injury in mice. Results: Treatment of the adult mouse inner ear with neomycin resulted in acute and chronic changes in endogenous neurotrophic factor gene expression and led to a degeneration of spiral ganglion cells. Increased survival of spiral ganglion cells after adenoviral delivery of BDNF or NTF3 to the inner ear was observed. Expression of BDNF and NT-3 could be demonstrated in the damaged organ of Corti after gene delivery. Hearing loss due to overexpression of neurotrophins in the normal hearing ear was avoided when using this novel vector–promoter combination. Conclusion: Combining supporting cell-specific gene delivery via the adenovirus serotype 28 vector with a low-strength long expressing promoter potentially can provide long-term neurotrophin delivery to the damaged inner ear.
Collapse
Affiliation(s)
| | | | - Anna Lawrence
- Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States
| | | | - Peixin Huang
- Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States
| | - Jennifer Harre
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Athanasia Warnecke
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Hinrich Staecker
- Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States
- *Correspondence: Hinrich Staecker,
| |
Collapse
|
7
|
van Dieken A, Staecker H, Schmitt H, Harre J, Pich A, Roßberg W, Lenarz T, Durisin M, Warnecke A. Bioinformatic Analysis of the Perilymph Proteome to Generate a Human Protein Atlas. Front Cell Dev Biol 2022; 10:847157. [PMID: 35573665 PMCID: PMC9096870 DOI: 10.3389/fcell.2022.847157] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 04/04/2022] [Indexed: 11/16/2022] Open
Abstract
The high complexity of the cellular architecture of the human inner ear and the inaccessibility for tissue biopsy hampers cellular and molecular analysis of inner ear disease. Sampling and analysis of perilymph may present an opportunity for improved diagnostics and understanding of human inner ear pathology. Analysis of the perilymph proteome from patients undergoing cochlear implantation was carried out revealing a multitude of proteins and patterns of protein composition that may enable characterisation of patients into subgroups. Based on existing data and databases, single proteins that are not present in the blood circulation were related to cells within the cochlea to allow prediction of which cells contribute to the individual perilymph proteome of the patients. Based on the results, we propose a human atlas of the cochlea. Finally, druggable targets within the perilymph proteome were identified. Understanding and modulating the human perilymph proteome will enable novel avenues to improve diagnosis and treatment of inner ear diseases.
Collapse
Affiliation(s)
- Alina van Dieken
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Hinrich Staecker
- Department of Otolaryngology, Head and Neck, Surgery, University of Kansas School of Medicine, Kansas City, KS, United States
| | - Heike Schmitt
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Jennifer Harre
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Andreas Pich
- Core Facility Proteomics, Hannover Medical School, Hannover, Germany
| | - Willi Roßberg
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Thomas Lenarz
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Martin Durisin
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| | - Athanasia Warnecke
- Department of Otolaryngology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
8
|
Wille I, Harre J, Oehmichen S, Lindemann M, Menzel H, Ehlert N, Lenarz T, Warnecke A, Behrens P. Development of Neuronal Guidance Fibers for Stimulating Electrodes: Basic Construction and Delivery of a Growth Factor. Front Bioeng Biotechnol 2022; 10:776890. [PMID: 35141211 PMCID: PMC8819688 DOI: 10.3389/fbioe.2022.776890] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 01/05/2022] [Indexed: 12/03/2022] Open
Abstract
State-of-the-art treatment for sensorineural hearing loss is based on electrical stimulation of residual spiral ganglion neurons (SGNs) with cochlear implants (CIs). Due to the anatomical gap between the electrode contacts of the CI and the residual afferent fibers of the SGNs, spatial spreading of the stimulation signal hampers focused neuronal stimulation. Also, the efficiency of a CI is limited because SGNs degenerate over time due to loss of trophic support. A promising option to close the anatomical gap is to install fibers as artificial nerve guidance structures on the surface of the implant and install on these fibers drug delivery systems releasing neuroprotective agents. Here, we describe the first steps in this direction. In the present study, suture yarns made of biodegradable polymers (polyglycolide/poly-ε-caprolactone) serve as the basic fiber material. In addition to the unmodified fiber, also fibers modified with amine groups were employed. Cell culture investigations with NIH 3T3 fibroblasts attested good cytocompatibility to both types of fibers. The fibers were then coated with the extracellular matrix component heparan sulfate (HS) as a biomimetic of the extracellular matrix. HS is known to bind, stabilize, modulate, and sustainably release growth factors. Here, we loaded the HS-carrying fibers with the brain-derived neurotrophic factor (BDNF) which is known to act neuroprotectively. Release of this neurotrophic factor from the fibers was followed over a period of 110 days. Cell culture investigations with spiral ganglion cells, using the supernatants from the release studies, showed that the BDNF delivered from the fibers drastically increased the survival rate of SGNs in vitro. Thus, biodegradable polymer fibers with attached HS and loaded with BDNF are suitable for the protection and support of SGNs. Moreover, they present a promising base material for the further development towards a future neuronal guiding scaffold.
Collapse
Affiliation(s)
- Inga Wille
- Institut für Anorganische Chemie, Leibniz Universität Hannover, Hannover, Germany
- Cluster of Excellence Hearing4all, Hannover, Germany
- *Correspondence: Inga Wille, ; Peter Behrens,
| | - Jennifer Harre
- Cluster of Excellence Hearing4all, Hannover, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany
| | - Sarah Oehmichen
- Institut für Technische Chemie, Technische Universität Braunschweig, Braunschweig, Germany
| | - Maren Lindemann
- Institut für Technische Chemie, Technische Universität Braunschweig, Braunschweig, Germany
| | - Henning Menzel
- Institut für Technische Chemie, Technische Universität Braunschweig, Braunschweig, Germany
| | - Nina Ehlert
- Institut für Anorganische Chemie, Leibniz Universität Hannover, Hannover, Germany
- Cluster of Excellence Hearing4all, Hannover, Germany
| | - Thomas Lenarz
- Cluster of Excellence Hearing4all, Hannover, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany
| | - Athanasia Warnecke
- Cluster of Excellence Hearing4all, Hannover, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany
| | - Peter Behrens
- Institut für Anorganische Chemie, Leibniz Universität Hannover, Hannover, Germany
- Cluster of Excellence Hearing4all, Hannover, Germany
- Cluster of Excellence PhoenixD, Hannover, Germany
- *Correspondence: Inga Wille, ; Peter Behrens,
| |
Collapse
|
9
|
Warnecke A, Harre J, Shew M, Mellott AJ, Majewski I, Durisin M, Staecker H. Successful Treatment of Noise-Induced Hearing Loss by Mesenchymal Stromal Cells: An RNAseq Analysis of Protective/Repair Pathways. Front Cell Neurosci 2021; 15:656930. [PMID: 34887728 PMCID: PMC8650824 DOI: 10.3389/fncel.2021.656930] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 09/20/2021] [Indexed: 12/15/2022] Open
Abstract
Mesenchymal stromal cells (MSCs) are an adult derived stem cell-like population that has been shown to mediate repair in a wide range of degenerative disorders. The protective effects of MSCs are mainly mediated by the release of growth factors and cytokines thereby modulating the diseased environment and the immune system. Within the inner ear, MSCs have been shown protective against tissue damage induced by sound and a variety of ototoxins. To better understand the mechanism of action of MSCs in the inner ear, mice were exposed to narrow band noise. After exposure, MSCs derived from human umbilical cord Wharton's jelly were injected into the perilymph. Controls consisted of mice exposed to sound trauma only. Forty-eight hours post-cell delivery, total RNA was extracted from the cochlea and RNAseq performed to evaluate the gene expression induced by the cell therapy. Changes in gene expression were grouped together based on gene ontology classification. A separate cohort of animals was treated in a similar fashion and allowed to survive for 2 weeks post-cell therapy and hearing outcomes determined. Treatment with MSCs after severe sound trauma induced a moderate hearing protective effect. MSC treatment resulted in an up-regulation of genes related to immune modulation, hypoxia response, mitochondrial function and regulation of apoptosis. There was a down-regulation of genes related to synaptic remodeling, calcium homeostasis and the extracellular matrix. Application of MSCs may provide a novel approach to treating sound trauma induced hearing loss and may aid in the identification of novel strategies to protect hearing.
Collapse
Affiliation(s)
- Athanasia Warnecke
- Clinic for Otolaryngology–Head & Neck Surgery, Hanover Medical School, Hanover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation (EXC 2177/1), Oldenburg, Germany
| | - Jennifer Harre
- Clinic for Otolaryngology–Head & Neck Surgery, Hanover Medical School, Hanover, Germany
- Cluster of Excellence “Hearing4all” of the German Research Foundation (EXC 2177/1), Oldenburg, Germany
| | - Matthew Shew
- Department of Otolaryngology–Head & Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
| | | | - Igor Majewski
- Clinic for Otolaryngology–Head & Neck Surgery, Hanover Medical School, Hanover, Germany
| | - Martin Durisin
- Clinic for Otolaryngology–Head & Neck Surgery, Hanover Medical School, Hanover, Germany
| | - Hinrich Staecker
- Department of Otolaryngology–Head & Neck Surgery, University of Kansas School of Medicine, Kansas City, KS, United States
| |
Collapse
|
10
|
Schmitt HA, Pich A, Prenzler NK, Lenarz T, Harre J, Staecker H, Durisin M, Warnecke A. Personalized Proteomics for Precision Diagnostics in Hearing Loss: Disease-Specific Analysis of Human Perilymph by Mass Spectrometry. ACS Omega 2021; 6:21241-21254. [PMID: 34471729 PMCID: PMC8387986 DOI: 10.1021/acsomega.1c01136] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 07/09/2021] [Indexed: 05/11/2023]
Abstract
Despite a vast amount of data generated by proteomic analysis on cochlear fluid, novel clinically applicable biomarkers of inner ear diseases have not been identified hitherto. The aim of the present study was to analyze the proteome of human perilymph from cochlear implant patients, thereby identifying putative changes of the composition of the cochlear fluid perilymph due to specific diseases. Sampling of human perilymph was performed during cochlear implantation from patients with clinically or radiologically defined inner ear diseases like enlarged vestibular aqueduct (EVA; n = 14), otosclerosis (n = 10), and Ménière's disease (n = 12). Individual proteins were identified by a shotgun proteomics approach and data-dependent acquisition, thereby revealing 895 different proteins in all samples. Based on quantification values, a disease-specific protein distribution in the perilymph was demonstrated. The proteins short-chain dehydrogenase/reductase family 9C member 7 and esterase D were detected in nearly all samples of Ménière's disease patients, but not in samples of patients suffering from EVA and otosclerosis. The presence of both proteins in the inner ear tissue of adult mice and neonatal rats was validated by immunohistochemistry. Whether these proteins have the potential for a biomarker in the perilymph of Ménière's disease patients remains to be elucidated.
Collapse
Affiliation(s)
- Heike A. Schmitt
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Andreas Pich
- Core
Facility Proteomics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Nils K. Prenzler
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Thomas Lenarz
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Jennifer Harre
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Hinrich Staecker
- Department
of Otolaryngology, Head and Neck Surgery, University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, United States
| | - Martin Durisin
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Athanasia Warnecke
- Department
of Otolaryngology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- Cluster
of Excellence of the German Research Foundation (DFG; “Deutsche
Forschungsgemeinschaft”) “Hearing4all”, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| |
Collapse
|
11
|
Warnecke A, Prenzler N, Harre J, Köhl U, Gärtner L, Lenarz T, Laner-Plamberger S, Wietzorrek G, Staecker H, Lassacher T, Hollerweger J, Gimona M, Rohde E. First-in-human intracochlear application of human stromal cell-derived extracellular vesicles. J Extracell Vesicles 2021; 10:e12094. [PMID: 34136108 PMCID: PMC8178433 DOI: 10.1002/jev2.12094] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 03/15/2021] [Accepted: 04/22/2021] [Indexed: 12/20/2022] Open
Abstract
Extracellular vesicles (EVs) derived from the secretome of human mesenchymal stromal cells (MSC) contain numerous factors that are known to exert anti‐inflammatory effects. MSC‐EVs may serve as promising cell‐based therapeutics for the inner ear to attenuate inflammation‐based side effects from cochlear implantation which represents an unmet clinical need. In an individual treatment performed on a ‘named patient basis’, we intraoperatively applied allogeneic umbilical cord‐derived MSC‐EVs (UC‐MSC‐EVs) produced according to good manufacturing practice. A 55‐year‐old patient suffering from Menière's disease was treated with intracochlear delivery of EVs prior to the insertion of a cochlear implant. This first‐in‐human use of UC‐MSC‐EVs demonstrates the feasibility of this novel adjuvant therapeutic approach. The safety and efficacy of intracochlear EV‐application to attenuate side effects of cochlea implants have to be determined in controlled clinical trials.
Collapse
Affiliation(s)
- Athanasia Warnecke
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Nils Prenzler
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Jennifer Harre
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Ulrike Köhl
- Institute for Cellular Therapeutics Hannover and Institute of Clinical Immunology Hannover Medical School University of Leipzig as well as Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig Germany
| | - Lutz Gärtner
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Thomas Lenarz
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Sandra Laner-Plamberger
- Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria
| | - Georg Wietzorrek
- Institute of Molecular and Cellular Pharmacology Medical University of Innsbruck Innsbruck Austria
| | - Hinrich Staecker
- Department of Otolaryngology Head and Neck Surgery University of Kansas School of Medicine Kansas City Kansas USA
| | - Teresa Lassacher
- GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.,Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria
| | - Julia Hollerweger
- GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.,Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria
| | - Mario Gimona
- Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria.,GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.,Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria.,Research and Transfer Centre for Extracellular Vesicle Theralytic Technologies Salzburg Austria
| | - Eva Rohde
- Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria.,GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.,Research and Transfer Centre for Extracellular Vesicle Theralytic Technologies Salzburg Austria
| |
Collapse
|
12
|
Heeger P, Harre J, Warnecke A, Mueller D, Kalies S, Heisterkamp A. Probing interneuronal cell communication via optogenetic stimulation. Translational Biophotonics 2021. [DOI: 10.1002/tbio.202100002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Affiliation(s)
- Patrick Heeger
- Leibniz University Hannover, Institute of Quantum Optics, AG Heisterkamp Hannover Germany
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- Cluster of Excellence Hearing4all Hannover Germany
| | - Jennifer Harre
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- Cluster of Excellence Hearing4all Hannover Germany
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Athanasia Warnecke
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- Cluster of Excellence Hearing4all Hannover Germany
- Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany
| | - Dominik Mueller
- Leibniz University Hannover, Institute of Quantum Optics, AG Heisterkamp Hannover Germany
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- REBIRTH Research Center for Translational Regenerative Medicine Hannover Germany
| | - Stefan Kalies
- Leibniz University Hannover, Institute of Quantum Optics, AG Heisterkamp Hannover Germany
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- REBIRTH Research Center for Translational Regenerative Medicine Hannover Germany
| | - Alexander Heisterkamp
- Leibniz University Hannover, Institute of Quantum Optics, AG Heisterkamp Hannover Germany
- Lower Saxony Centre for Biomedical Engineering, Implant Research and Development Hannover Germany
- Cluster of Excellence Hearing4all Hannover Germany
- REBIRTH Research Center for Translational Regenerative Medicine Hannover Germany
| |
Collapse
|
13
|
Harre J, Heinkele L, Steffens M, Warnecke A, Lenarz T, Just I, Rohrbeck A. Potentiation of Brain-Derived Neurotrophic Factor-Induced Protection of Spiral Ganglion Neurons by C3 Exoenzyme/Rho Inhibitor. Front Cell Neurosci 2021; 15:602897. [PMID: 33776650 PMCID: PMC7991574 DOI: 10.3389/fncel.2021.602897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Accepted: 02/19/2021] [Indexed: 11/17/2022] Open
Abstract
Preservation of the excitability of spiral ganglion neurons (SGN) may contribute to an improved speech perception after cochlear implantation. Thus, the application of exogenous neurotrophic factors such as the neurotrophin brain-derived neurotrophic factor (BDNF) to increase SGN survival in vitro and in vivo is a promising pharmacological approach in cochlear implant (CI) research. Due to the difficult pharmacokinetic profile of proteins such as BDNF, there is a quest for small molecules to mediate the survival of SGN or to increase the efficacy of BDNF. The C3 exoenzyme from Clostridium botulinum could be a potential new candidate for the protection and regeneration of SGN. Inhibition of the RhoA GTPase pathway which can be mediated by C3 is described as a promising strategy to enhance axonal regeneration and to exert pro-survival signals in neurons. Nanomolar concentrations of C3, its enzymatically inactive form C3E174Q, and a 26mer C-terminal peptide fragment covering amino acid 156–181 (C3156-181) potentiated the neuroprotective effect on SGN mediated by BDNF in vitro. The neuroprotective effect of C3/BDNF was reduced to the neuroprotective effect of BDNF alone after the treatment with wortmannin, an inhibitor of the phosphatidylinositol-3-kinase (PI3K).The exoenzyme C3 (wild-type and enzyme-deficient) and the C3 peptide fragment C3154–181 present novel biologically active compounds for the protection of the SGN. The exact underlying intracellular mechanisms that mediate the neuroprotective effect are not clarified yet, but the combination of BDNF (TrkB stimulation) and C3 exoenzyme (RhoA inhibition) can be used to protect SGN in vitro.
Collapse
Affiliation(s)
- Jennifer Harre
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany.,Cluster of Excellence "Hearing4all" of the German Research Foundation (EXC 2177/1), Hannover, Germany
| | - Laura Heinkele
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany
| | - Melanie Steffens
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany
| | - Athanasia Warnecke
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany.,Cluster of Excellence "Hearing4all" of the German Research Foundation (EXC 2177/1), Hannover, Germany
| | - Thomas Lenarz
- Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, Hannover, Germany.,Cluster of Excellence "Hearing4all" of the German Research Foundation (EXC 2177/1), Hannover, Germany
| | - Ingo Just
- Institute of Toxicology, Hannover Medical School, Hannover, Germany
| | - Astrid Rohrbeck
- Institute of Toxicology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
14
|
Warnecke A, Harre J, Staecker H, Prenzler N, Strunk D, Couillard‐Despres S, Romanelli P, Hollerweger J, Lassacher T, Auer D, Pachler K, Wietzorrek G, Köhl U, Lenarz T, Schallmoser K, Laner‐Plamberger S, Falk CS, Rohde E, Gimona M. Extracellular vesicles from human multipotent stromal cells protect against hearing loss after noise trauma in vivo. Clin Transl Med 2020; 10:e262. [PMID: 33377658 PMCID: PMC7752163 DOI: 10.1002/ctm2.262] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 12/03/2020] [Accepted: 12/06/2020] [Indexed: 12/21/2022] Open
Abstract
The lack of approved anti-inflammatory and neuroprotective therapies in otology has been acknowledged in the last decades and recent approaches are heralding a new era in the field. Extracellular vesicles (EVs) derived from human multipotent (mesenchymal) stromal cells (MSC) can be enriched in vesicular secretome fractions, which have been shown to exert effects (eg, neuroprotection and immunomodulation) of their parental cells. Hence, MSC-derived EVs may serve as novel drug candidates for several inner ear diseases. Here, we provide first evidence of a strong neuroprotective potential of human stromal cell-derived EVs on inner ear physiology. In vitro, MSC-EV preparations exerted immunomodulatory activity on T cells and microglial cells. Moreover, local application of MSC-EVs to the inner ear significantly attenuated hearing loss and protected auditory hair cells from noise-induced trauma in vivo. Thus, EVs derived from the vesicular secretome of human MSC may represent a next-generation biological drug that can exert protective therapeutic effects in a complex and nonregenerating organ like the inner ear.
Collapse
Affiliation(s)
- Athanasia Warnecke
- Department of OtorhinolaryngologyHead and Neck SurgeryHannover Medical SchoolHannoverGermany
| | - Jennifer Harre
- Department of OtorhinolaryngologyHead and Neck SurgeryHannover Medical SchoolHannoverGermany
| | - Hinrich Staecker
- Department of Otolaryngology, Head and Neck SurgeryUniversity of Kansas School of MedicineKansas CityKansas
| | - Nils Prenzler
- Department of OtorhinolaryngologyHead and Neck SurgeryHannover Medical SchoolHannoverGermany
| | - Dirk Strunk
- Institute of Experimental and Clinical Cell TherapySpinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical UniversitySalzburgAustria
| | - Sebastien Couillard‐Despres
- Institute of Experimental NeuroregenerationSpinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical UniversitySalzburgAustria
- Austrian Cluster for Tissue RegenerationViennaAustria
| | - Pasquale Romanelli
- Institute of Experimental NeuroregenerationSpinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical UniversitySalzburgAustria
| | - Julia Hollerweger
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
| | - Teresa Lassacher
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
| | - Daniela Auer
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
| | - Karin Pachler
- Research Program “Nanovesicular Therapies,”Paracelsus Medical University (PMU)SalzburgAustria
| | - Georg Wietzorrek
- Institute of Molecular and Cellular PharmacologyMedical University of InnsbruckInnsbruckAustria
| | - Ulrike Köhl
- Institute of Cellular TherapeuticsHannover Medical School and Clinical ImmunologyUniversity Leipzig, Fraunhofer Institute for Cell Therapy and ImmunologyLeipzigGermany
| | - Thomas Lenarz
- Department of OtorhinolaryngologyHead and Neck SurgeryHannover Medical SchoolHannoverGermany
| | - Katharina Schallmoser
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
- Department of Transfusion MedicineUniversity HospitalSalzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU)SalzburgAustria
| | - Sandra Laner‐Plamberger
- Department of Transfusion MedicineUniversity HospitalSalzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU)SalzburgAustria
| | - Christine S. Falk
- Institute of Transplant ImmunologyHannover Medical SchoolHannoverGermany
| | - Eva Rohde
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
- Department of Transfusion MedicineUniversity HospitalSalzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU)SalzburgAustria
| | - Mario Gimona
- GMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI‐TReCS)Paracelsus Medical University (PMU)SalzburgAustria
- Research Program “Nanovesicular Therapies,”Paracelsus Medical University (PMU)SalzburgAustria
| |
Collapse
|
15
|
Affiliation(s)
- J Harre
- Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana 70112-2699
| | | |
Collapse
|
16
|
|